OCSOculis Holding - Ordinary sharesOCS info
$11.95info0.00%24h
Global rank12262
Market cap$435.40M
Change 7d-
YTD Performance5.75%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Oculis Holding - Ordinary shares (OCS) Stock Overview

    Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

    OCS Stock Information

    Symbol
    OCS
    Address
    Bahnhofstrasse 7Zug, 6300Switzerland
    Founded
    -
    Trading hours
    -
    Website
    https://oculis.com
    Country
    🇨🇭 Switzerland
    Phone Number
    41 58 810 0182

    Oculis Holding - Ordinary shares (OCS) Price Chart

    -
    Value:-

    Oculis Holding - Ordinary shares Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $11.95
    N/A
    Market Cap
    $435.40M
    N/A
    Shares Outstanding
    36.44M
    N/A
    Employees
    28.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org